Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Beta Drugs's Enterprise Value is ₹11,264 Mil.
Beta Drugs's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹516 Mil. Therefore, Beta Drugs's EV-to-EBIT ratio for today is 21.84.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Beta Drugs's Enterprise Value is ₹11,264 Mil.
Beta Drugs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₹614 Mil. Therefore, Beta Drugs's EV-to-EBITDA ratio for today is 18.36.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Beta Drugs's Enterprise Value is ₹11,264 Mil.
Beta Drugs's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₹2,957 Mil. Therefore, Beta Drugs's EV-to-Revenue ratio for today is 3.81.
Beta Drugs Enterprise Value Historical Data
The historical data trend for Beta Drugs's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Beta Drugs's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Beta Drugs's Enterprise Value falls into.
Beta Drugs Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Beta Drugs's Enterprise Value for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs (NSE:BETA) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Beta Drugs's current Enterprise Value is ₹11,264 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Beta Drugs's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹516 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Beta Drugs's current Enterprise Value is ₹11,264 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Beta Drugs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₹614 Mil.
Beta Drugs's current Enterprise Value is ₹11,264 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Beta Drugs's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₹2,957 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs Enterprise Value Related Terms
Thank you for viewing the detailed overview of Beta Drugs's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports it to other countries of which key revenue is derived from the sales made in India.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NSE:BETA has been successfully added to your 